JP2010510223A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010510223A5 JP2010510223A5 JP2009537223A JP2009537223A JP2010510223A5 JP 2010510223 A5 JP2010510223 A5 JP 2010510223A5 JP 2009537223 A JP2009537223 A JP 2009537223A JP 2009537223 A JP2009537223 A JP 2009537223A JP 2010510223 A5 JP2010510223 A5 JP 2010510223A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- tim
- antigen
- activity
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85939106P | 2006-11-15 | 2006-11-15 | |
| US92394507P | 2007-04-17 | 2007-04-17 | |
| PCT/US2007/024067 WO2008060617A2 (en) | 2006-11-15 | 2007-11-15 | Therapeutic uses of tim-3 modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010510223A JP2010510223A (ja) | 2010-04-02 |
| JP2010510223A5 true JP2010510223A5 (enExample) | 2012-01-26 |
Family
ID=39402274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009537223A Withdrawn JP2010510223A (ja) | 2006-11-15 | 2007-11-15 | Ｔｉｍ−３調節物質の治療的使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20100061992A1 (enExample) |
| EP (1) | EP2081961A2 (enExample) |
| JP (1) | JP2010510223A (enExample) |
| AU (1) | AU2007319806A1 (enExample) |
| CA (1) | CA2668693A1 (enExample) |
| WO (1) | WO2008060617A2 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010084999A1 (en) * | 2009-01-26 | 2010-07-29 | Protegene, Inc. | Immunosuppressive agents and prophylactic and therapeutic agents for autoimmune diseases |
| KR101856462B1 (ko) * | 2009-03-25 | 2018-05-10 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 병원체에 대한 포유동물의 선천성 면역 저항성의 자극을 위한 조성물 |
| CN103079644B (zh) * | 2010-06-11 | 2017-02-15 | 协和发酵麒麟株式会社 | 抗tim‑3抗体 |
| WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| JP2015525781A (ja) | 2012-07-31 | 2015-09-07 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | 免疫応答の調節 |
| US20140120157A1 (en) * | 2012-09-19 | 2014-05-01 | Georgetown University | Targeted liposomes |
| WO2014059251A1 (en) | 2012-10-12 | 2014-04-17 | The Brigham And Women's Hospital, Inc. | Enhancement of the immune response |
| EA031234B1 (ru) * | 2012-10-29 | 2018-12-28 | Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Арканзас | Вакцина с адъювантом на основе маннозилированного хитозана |
| EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| PL3099717T3 (pl) | 2014-01-31 | 2019-10-31 | Novartis Ag | Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie |
| US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| KR20200029627A (ko) * | 2014-03-12 | 2020-03-18 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소 |
| US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| EA201691765A1 (ru) | 2014-03-14 | 2016-12-30 | Новартис Аг | Молекулы антител против lag-3 и их применения |
| LT3148579T (lt) | 2014-05-28 | 2021-05-25 | Agenus Inc. | Anti-gitr antikūnai ir jų panaudojimo būdai |
| EP3191126B1 (en) | 2014-09-13 | 2020-05-13 | Novartis AG | Combination therapies of alk inhibitors |
| WO2016171722A1 (en) * | 2015-04-24 | 2016-10-27 | The Brigham And Women's Hospital, Inc. | Interactions between ceacam and tim family members |
| WO2016179194A1 (en) * | 2015-05-04 | 2016-11-10 | Jounce Therapeutics, Inc. | Lilra3 and method of using the same |
| MX2017016844A (es) | 2015-07-16 | 2018-08-15 | Biokine Therapeutics Ltd | Composiciones y procedimientos para tratar cancer. |
| US20180340025A1 (en) | 2015-07-29 | 2018-11-29 | Novartis Ag | Combination therapies comprising antibody molecules to lag-3 |
| WO2017096179A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Antibodies and methods of use thereof |
| CN108495651A (zh) | 2015-12-17 | 2018-09-04 | 诺华股份有限公司 | 抗pd-1的抗体分子及其用途 |
| US20190367552A1 (en) * | 2016-03-04 | 2019-12-05 | Galectin Sciences, Llc | Selenogalactoside compounds for the prevention and treatment of diseases associated with galectin and the use thereof |
| FR3051192B1 (fr) * | 2016-05-13 | 2020-12-25 | Univ De Lorraine | Methode de purification de proteines recombinantes par affinite basee sur l'activite lectinique du domaine crd d'une galectine |
| KR102543118B1 (ko) | 2016-05-27 | 2023-06-14 | 아게누스 인코포레이티드 | 항-tim-3 항체 및 이의 사용 방법 |
| US20190248893A1 (en) | 2016-07-14 | 2019-08-15 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
| KR102626669B1 (ko) | 2017-05-12 | 2024-01-17 | 갈랙틴 사이언시즈, 엘엘씨 | 질환의 예방 및 치료를 위한 화합물 및 이의 용도 |
| CN111201030B (zh) * | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
| KR102572804B1 (ko) * | 2020-02-25 | 2023-08-31 | 국립암센터 | CD11b+ 세포에서 TIM-3의 발현 수준을 측정하는 암 진단 또는 예후 예측을 위한 정보제공 방법 |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| WO2022236370A1 (en) * | 2021-05-11 | 2022-11-17 | Griffith University | Immunogenic composition |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4694128B2 (ja) * | 2002-01-30 | 2011-06-08 | ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド | ＴＩＭ−３、Ｔｈ１特異的細胞表面分子に関連した組成物および方法 |
| JP2008500013A (ja) * | 2003-10-03 | 2008-01-10 | ザ ブライハム アンド ウイメンズ ホスピタル，インコーポレイテッド | Ｔｉｍ−３ポリペプチド |
-
2007
- 2007-11-15 AU AU2007319806A patent/AU2007319806A1/en not_active Abandoned
- 2007-11-15 EP EP07867488A patent/EP2081961A2/en not_active Withdrawn
- 2007-11-15 WO PCT/US2007/024067 patent/WO2008060617A2/en not_active Ceased
- 2007-11-15 US US12/514,602 patent/US20100061992A1/en not_active Abandoned
- 2007-11-15 JP JP2009537223A patent/JP2010510223A/ja not_active Withdrawn
- 2007-11-15 CA CA002668693A patent/CA2668693A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7215997B2 (ja) | 前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法 | |
| Foote et al. | A STING agonist given with OX40 receptor and PD-L1 modulators primes immunity and reduces tumor growth in tolerized mice | |
| US10392444B2 (en) | Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer | |
| Fury et al. | A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors | |
| Cook et al. | Granulocyte macrophage colony-stimulating factor receptor α expression and its targeting in antigen-induced arthritis and inflammation | |
| US20100310501A1 (en) | Methods for Improving Immune Function and Methods for Prevention or Treatment of Disease in a Mammalian Subject | |
| Weber et al. | Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF‐3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma | |
| JP2004501631A5 (enExample) | ||
| AU2010248935B2 (en) | Methods and compositions for treating lupus | |
| JP2006523682A5 (enExample) | ||
| US20030007972A1 (en) | Cytokine antagonists and other biologics for the treatment of bone metastases | |
| JP2011507891A5 (enExample) | ||
| JP2002537362A (ja) | ビオチン化ケモカイン抗体複合体 | |
| De Benedetti et al. | In vivo neutralization of human IL-6 (hIL-6) achieved by immunization of hIL-6-transgenic mice with a hIL-6 receptor antagonist | |
| US20220249621A1 (en) | TREATMENT OF CANCERS USING sEphB4-HSA FUSION PROTEINS | |
| JP2024028454A (ja) | 糖尿病、肝炎、および／または炎症性肝疾患を治療するための方法 | |
| CA3118706A1 (en) | B-cell activating cd73 antibodies | |
| KR20200068746A (ko) | Il8의 emt 경로 차단 및 암 줄기 세포 극복(il8 bloking emt pathway and overcoming cancer stem cells) | |
| JP2002504910A (ja) | 治療用タンパク質阻害因子症候群のためのｃｄ１５４遮断治療 | |
| Lampson | Beyond inflammation: site-directed immunotherapy | |
| Ibtehaj et al. | B cell-specific mAb–siRNA conjugates improve experimental myasthenia | |
| WO2020096046A1 (ja) | 老化関連ｔ細胞を標的とした糖代謝異常の予防または治療用ワクチン | |
| Shao | Biologic therapy in Sjögren’s syndrome | |
| Koschella et al. | CD40 ligation in vivo induces bystander proliferation of memory phenotype CD8 T cells | |
| Kim et al. | Protective effect of the DNA vaccine encoding the major house dust mite allergens on allergic inflammation in the murine model of house dust mite allergy |